[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endocarditis-acute-and-subacute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endocarditis-acute-and-subacute":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100652276","localized-evidence-of-cytokine-adsorption-therapy-during-pediatric-cardiac-surgery-a-single-center-randomized-controlled-trial-leat-100652276",false,"NCT07771491","Localized Evidence of Cytokine Adsorption Therapy During Pediatric Cardiac Surgery: A Single Center Randomized Controlled Trial (LEAT)","LEAT","Inclusion Criteria:\n\n* Children (\\\u003C18 years old at study inclusion)\n* Undergoing a cardiac surgery with CPB of expected duration \\> 180min\n* Prophylactic application of HA during CPB for suspected SIRS.\n\nExclusion Criteria:\n\n* Non-ability to gather informed consent from parents or legal representative. Enrolled in conflicting research study\n* Off-pump procedure\n* Non-steroidal anti-inflammatory treatment in the previous 7 days Pregnancy","ALL","0 Years","17 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Localized Evidence of Cytokine Adsorption Therapy (LEAT) study is a prospective, randomized controlled trial conducted at the Institut Jantung Negara in Malaysia. It evaluates the efficacy and safety of using Jafron HA-60 and HA380 hemoadsorption cartridges to reduce systemic inflammation in pediatric patients undergoing major heart surgery.\n\nObjective This study aims to compare the post-operative inflammatory response in children undergoing cardiac procedures treated with or without a cytokine.\n\nStudy Population All children \\\u003C 18 years of age at the time of enrollment who are scheduled to undergo cardiac surgery involving cardiopulmonary bypass (CPB) with an expected duration of \\>180 minutes.\n\nMethodology This single-center study will randomly assign patients before surgery into 2 groups: 1 group will receive hemoadsorption treatment plus with standard-of-care (intervention group), while the other group will receive standard-of-care (control group) only.\n\nPrimary Endpoint:\n\nTo evaluate changes in IL-6 plasma concentrations over the first 24 hours following the procedure. Analysis will be performed using a linear mixed-effects model (LMM) to capture both between-subject and within-subject variability across repeated time points. This method allows assessment of the overall trajectory of IL-6 and provides a clearer understanding of its temporal pattern throughout the 24-hour post-procedure period.\n\nSecondary Endpoints:\n\n1. Changes cytokines (IL-8, IL-10, IL-1β, and TNF-α) plasma levels over 24 hours\n2. PELOD-2 score on ICU admission, at 48 hours post ICU admission\n3. ICU and hospital length of stay\n4. ICU, hospital, and 28 days mortality\n5. Mechanical - ventilation (MV) free days at day\n6. Renal replacement therapy (RRT) free days at day 28\n7. Vasopressors free days at day 28\n8. Acute kidney injury\n9. Bleeding complications\n10. Post operative liver injury\n\nData Collection:\n\nBlood samples will be taken at five timepoints: before surgery, at ICU admission, and at 6, 24, and 48 hours post-procedure .\n\nDuration: The study is expected to last 24 months.",[27,28,29,30,31],"Congenital Heart Disease","Open Heart Surgery","Cardiopulmonary Bypass","Endocarditis Acute and Subacute","Cyanotic Heart Disease","NOT_YET_RECRUITING","2026-08-13",{"date":35,"type":36},"2026-08-18","ACTUAL",{"date":38,"type":21},"2026-10-01",{"date":40,"type":21},"2028-10-31",{"name":42,"class":43},"Norfaniza Zabidi","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100486427","effectiveness-of-antibiotic-prophylaxis-of-infective-endocarditis-for-invasive-dental-procedures-in-patients-with-prosthetic-heart-valves-andor-history-of-infective-endocarditis-100486427","NCT05613933","Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and\u002For History of Infective Endocarditis","Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis Before Invasive Dental Procedures in Patients With Prosthetic Heart Valves and\u002For History of Infective Endocarditis: a Prospective, Registry-based, Cluster-randomized Trial in Primary Care","PROPHETS","Inclusion Criteria:\n\n* All French Health Territories (Territoires de santé, TDS) will be included and each TDS will contribute as a cluster for randomization.\n* All dentists working in each TDS will be included.\n* Among individuals receiving an invasive dental procedure, all patients aged 18 years or more identified with prosthetic heart valves or recorded with prior infective endocarditis will be included.\n\nExclusion Criteria:\n\n* No exclusion criteria for health territories, dentists and patient.\n* However, dental procedures that had been performed less than 6 months after the date of first implantation of prosthetic heart valve won't be included.","18 Years",{"count":54,"type":21},250000,[24],"Infective endocarditis (IE) continues to cause serious morbidity and mortality. To reduce its incidence, antibiotic prophylaxis has been recommended before invasive dental procedures in patients with at risk predispositions. Several studies have examined the effect of antibiotic prophylaxis on the incidence of IE and have brought conflicting results. The investigators aim to evaluate the effectiveness of antibiotic prophylaxis before invasive dental procedures to prevent oral streptococcal infective endocarditis in patients with prosthetic heart valves and\u002For history of IE, using a registry-based, cluster-randomized, controlled trial. In secondary objectives, the investigators aim to analyze changes in dentists' practices.",[58,59,30],"Endocarditis, Bacterial","Endocarditis",[61,62,63,64,65],"Registry based randomized controlled trial","antibiotic prophylaxy","dentist","invasive dental procedure","infective endocarditis","2023-01-31",{"date":68,"type":36},"2023-02-02",{"date":70,"type":21},"2023-02-01",{"date":72,"type":21},"2027-12-31",{"name":74,"class":43},"University Hospital, Bordeaux"]